Fig 9. Nilotinib resistant T315I mutant cells are still sensitive to KPC34.

Baf-3 cells expressing either wild type (WT) or T315I mutant BCR-ABL (T315I) were treated with the indicated amount of nilotinib or KPC3 for 72 hours and viability assessed. Shown are the averages of 3 independent experiments each done in triplicate.